Moderna beats Wall Street estimates for first-quarter profit and sales [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine. The U.S. vaccine maker also said it did not expect to get regulator approval for its combination shot to protect against both COVID-19 and influenza until 2026, after the U.S. Food and Drug Administration said it required late-stage data demonstrating the shot's efficacy against the flu. Moderna previously said it hoped to launch the vaccine for the autumn respiratory disease season in 2025 or 2026. The Cambridge, Massachusetts-based drugmaker said it plans to cut its adjusted operating costs by as much as $1.7 billion by 2027 compared to its estimate for this year. It expects operating costs for 2027 to be between $4.7 billion and $5 billion, the company said. Finance chief James Mock said in an interview Moderna expects those costs to fall as it completes several late-stage vaccine trials. Moderna posted an adjusted loss of $2.52 per share for the quarter, beating analysts' estimat
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Evaluating Novavax's Current Valuation After Steep Five Year Share Price Collapse [Yahoo! Finance]Yahoo! Finance
- Pfizer leads COVID-19 vaccine peers lower after revamped guidance [Seeking Alpha]Seeking Alpha
- New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use [Yahoo! Finance]Yahoo! Finance
- Why I Wouldn't Touch Novavax With a 10-Foot Pole [Yahoo! Finance]Yahoo! Finance
- Novavax (NASDAQ:NVAX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 12/15/25 - Form 4
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 8-K
- NVAX's page on the SEC website